Company Overview and News

34
Market Update: PSU banks push Nifty higher led by BoB, PNB; RIL, GAIL up 1-3%, PC Jeweller zooms 38%

2018-05-07 moneycontrol
The Indian equity market extended gains and was trading on a positive note on Monday afternoon with the Nifty gaining 79 points and was trading at a shade below 10,700 at 10,697 while the Sensex was up 248 points or 0.71 percent.
500325 532714 539437 532483 534816 GAILF CLNDY RLNIY SBAZ TVSMOTOR AXB 501425 APOLLOTYRE YYBKY AYRQY BBTC CNRYY AXBA GAILY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA BHRYY 533150 RELIANCE 533273 TTNQY 533278 532215 532343 532540 IDFCBANK 532461 AXISBANK RIGD INFRATEL KEC YESBANK HINDALCO 500877 IBN 532648 AXBKY HNDNF ICICIBANK OBZIY GODREJPROP OBEROIRLTY PNJZY 532174 501455 PNB GREAVESCOT 500440

39
Market Update: Axis Bank, Hindalco up 2-3% while Lupin sheds 3%; Jubilant Food hits new 52-week high

2018-05-07 moneycontrol
The Indian equity market extended loses was trading on a negative note on Monday afternoon with the Nifty gaining 36 points was trading at 10,654 while the Sensex was up 96 points or 0.28 percent.
531500 539437 532960 532483 EICHERMOT CLNDY SBAZ RAJESHEXPO AXB 501425 BBTC CNRYY AXBA TATASTEEL TATLY 534809 TCS HINDPETRO PCJEWELLER 500104 CANBK COALINDIA 533150 533273 TTNQY 533278 IDBLZ 532215 505200 500470 532540 IDFCBANK 532461 AXISBANK ECQRY HINDALCO IBVENTURES IBN AXBKY HNDNF ICICIBANK OBZIY GODREJPROP TTST OBEROIRLTY PNJZY 532174 PNB 500440

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...